QTRX vs. FLDM, LAB, CTKB, EYPT, PACB, NAUT, HBIO, SEER, AKYA, and BNGO
Should you be buying Quanterix stock or one of its competitors? The main competitors of Quanterix include Fluidigm (FLDM), Standard BioTools (LAB), Cytek Biosciences (CTKB), EyePoint Pharmaceuticals (EYPT), Pacific Biosciences of California (PACB), Nautilus Biotechnology (NAUT), Harvard Bioscience (HBIO), Seer (SEER), Akoya Biosciences (AKYA), and Bionano Genomics (BNGO).
Fluidigm (NASDAQ:FLDM) and Quanterix (NASDAQ:QTRX) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their earnings, institutional ownership, profitability, analyst recommendations, community ranking, risk, valuation, dividends and media sentiment.
Fluidigm has a beta of 1.14, indicating that its stock price is 14% more volatile than the S&P 500. Comparatively, Quanterix has a beta of 1.41, indicating that its stock price is 41% more volatile than the S&P 500.
In the previous week, Quanterix had 4 more articles in the media than Fluidigm. MarketBeat recorded 4 mentions for Quanterix and 0 mentions for Fluidigm. Fluidigm's average media sentiment score of 1.60 beat Quanterix's score of 0.28 indicating that Quanterix is being referred to more favorably in the news media.
Quanterix has a consensus target price of $30.60, suggesting a potential upside of 91.61%.
Fluidigm received 249 more outperform votes than Quanterix when rated by MarketBeat users. Likewise, 65.57% of users gave Fluidigm an outperform vote while only 61.66% of users gave Quanterix an outperform vote.
76.6% of Fluidigm shares are held by institutional investors. Comparatively, 86.5% of Quanterix shares are held by institutional investors. 2.9% of Fluidigm shares are held by insiders. Comparatively, 6.9% of Quanterix shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.
Quanterix has lower revenue, but higher earnings than Fluidigm. Quanterix is trading at a lower price-to-earnings ratio than Fluidigm, indicating that it is currently the more affordable of the two stocks.
Quanterix has a net margin of -28.82% compared to Quanterix's net margin of -45.36%. Fluidigm's return on equity of -10.39% beat Quanterix's return on equity.
Summary
Quanterix beats Fluidigm on 11 of the 16 factors compared between the two stocks.
Get Quanterix News Delivered to You Automatically
Sign up to receive the latest news and ratings for QTRX and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding QTRX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Quanterix Competitors List
Related Companies and Tools
